These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 730)

  • 1. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 2. Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP; Breese GR; Prange AJ
    Pharmacol Biochem Behav; 1975; 3(4):665-70. PubMed ID: 810812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.
    Klusha B; Georgiev V; Petkov V; Markovska V
    Acta Physiol Pharmacol Bulg; 1983; 9(2):14-9. PubMed ID: 6140814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
    Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
    Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOPA potentiation in ablated animals and brain levels of biogenic amines in intact animals after prolyl-leucylglycinamide.
    Plotnikoff NP; Minard FN; Kastin AJ
    Neuroendocrinology; 1974; 14(5):271-9. PubMed ID: 4858836
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological studies with a tripeptide, prolyl-leucyl glycine amide.
    Plotnikoff NP; Kastin AJ
    Arch Int Pharmacodyn Ther; 1974 Oct; 211(2):211-24. PubMed ID: 4156639
    [No Abstract]   [Full Text] [Related]  

  • 9. Potentiation of apomorphine action in rats by l-prolyl-l-leucyl-glycine amide.
    Kostrzewa RM; Kastin AJ; Sobrian SK
    Pharmacol Biochem Behav; 1978 Sep; 9(3):375-8. PubMed ID: 30981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolyl-leucyl-glycinamide, thyrotropin-releasing hormone and beta-endorphin-(10-16), like antidepressants, antagonize melatonin-induced behavioural changes in rats.
    Hatta K; Wolterink G; Van Ree JM
    Eur J Pharmacol; 1995 Sep; 284(3):327-30. PubMed ID: 8666016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of melanostatin on the central nervous system].
    Chepurnova NE; Borzenkov VM; Chepurnov SA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (2):36-42. PubMed ID: 6132624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
    Pugsley TA; Lippmann W
    Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Neuropharmacology of hypothalamic releasing factors.
    Plotnikoff NP; Kastin AJ
    Biochem Pharmacol; 1976 Feb; 25(4):363-5. PubMed ID: 7268
    [No Abstract]   [Full Text] [Related]  

  • 14. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP; De Carolis AS; Longo VG
    Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
    [No Abstract]   [Full Text] [Related]  

  • 15. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyrotropin releasing hormone: enhancement of DOPA activity in thyroidectomized rats.
    Plotnikoff NP; Prange AJ; Breese GR; Wilson IC
    Life Sci; 1974 Apr; 14(7):1271-8. PubMed ID: 4207315
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa potentiating analogs of Pro-Leu-Gly-NH2 with oral efficacy.
    Albrecht HP; Hofman HP; Klebe G; Kreiskott H
    Boll Chim Farm; 1991 Feb; 130(2):55-9. PubMed ID: 1678611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of hypothalamic releasing hormones in animals and men.
    Prange AJ; Wilson IC; Breese GR; Lipton MA
    Prog Brain Res; 1975; 42():1-9. PubMed ID: 729
    [No Abstract]   [Full Text] [Related]  

  • 19. Antagonism of morphine-induced catalepsy by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Mishra RK
    Eur J Pharmacol; 1979 Jan; 53(2):119-25. PubMed ID: 32058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review.
    Mishra RK; Chiu S; Chiu P; Mishra CP
    Methods Find Exp Clin Pharmacol; 1983; 5(4):203-33. PubMed ID: 6136640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.